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Summary
Objective: To assess the relative efﬁcacy of three different omega-3 (n-3) polyunsaturated fatty acids (PUFAs) in suppressing the mRNA
levels for important proteins involved in the etiology of osteoarthritis (OA).
Methods: A model cell culture system (bovine chondrocytes) was used. Inﬂammatory factors and enzymes involved in OA were induced by
exposure of the chondrocyte cultures to interleukin-1a (IL-1a). The effect of pre-incubating cultures with various amounts of exogenous fatty
acids on subsequent levels of mRNAs was assessed by reverse transcription-polymerase chain reactions (RT-PCR).
Results: Exposureof cultures to IL-1a inducedexpressionof the cartilageproteinasesADisintegrinAndMetalloproteinasewithThromboSpondin
motifs (ADAMTS)-4 and ADAMTS-5, cyclooxygenase (COX)-2, the matrix metalloproteinase (MMP)-3 and the inﬂammatory cytokines IL-1a, in-
terleukin-1b (IL-1b) and tumour necrosis factor-a (TNF-a). n-3 PUFAswere able to reduce the levels ofmRNA for ADAMTS-4, ADAMTS-5,MMP-
3, MMP-13, COX-2 (but not COX-1), IL-1a, IL-1b and TNF-a. Eicosapentaenoic acid (EPA) was themost effective, followed by docosahexaenoic
(DHA) and then a-linolenic (ALA) acid. The n-6 PUFA, arachidonic acid (AA) had no effect.
Conclusion: These results show that omega-3 (n-3) PUFAs cause a reduction in the mRNA levels for various proteins known to be important in
the pathology of OA. They provide a molecular explanation, at least in part, for beneﬁcial effects of dietary omega-3 PUFAs for the amelio-
ration of symptoms of the disease. The relative efﬁcacy of EPA suggests that this omega-3 PUFA may be especially useful for dietary sup-
plementation in patients with OA.
Crown Copyright ª 2009 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. All rights reserved.
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Osteoarthritis (OA) is a common, chronic disease, charac-
terised by joint inﬂammation and, in early stages, increased
catabolism of the proteoglycan aggrecan, followed by later
loss of type II collagen which cumulatively leads to destruc-
tion of the joint cartilage1. Primary OA occurs in middle
aged or elderly patients and is presumed to reﬂect joint
‘wear and tear’. It remains a major health problem of the
elderly2. Secondary OA occurs at any age as a result of
trauma or disease1. One of the major causes of secondary
OA is biomechanical joint instability, leading to biochemical
changes within the extracellular matrices of the joint tis-
sues3. A central feature is loss of articular cartilage (caused
by increased matrix degradation) and a reduced capacity
for repair. The cyclic disease course of OA has been pro-
posed to be due to sequential cytokine effects elevating
proteinase activity with the pro-inﬂammatory cytokines
such as interleukin-1 (IL-1) and tumour necrosis factor-
a (TNF-a) important1 in these metabolic processes.
Two families of metalloproteinases, matrix metalloprotei-
nases (MMPs) and A Disintegrin And Metalloproteinase
with ThromboSpondin motifs (ADAMTSs,) degrade theaPresent address: Malaysian Palm Oil Board, Persiaran Institusi,
43000 Kajang, Selangor, Malaysia.
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896major components of the cartilage matrix, namely aggrecan
and type II collagen4. The major site for cleavage of aggre-
can is the Glu373-Ala374 bond within the interglobular
domain1 of the aggrecan core protein which is hydrolysed
by aggrecanases5,6. It is mainly cleavage at this site that
is responsible for the increased aggrecan degradation
seen in inﬂammatory joint disease7. The catabolites have
been found in the synovial ﬂuid of patients with OA and
accumulate in model experimental systems (cartilage
explants or chondrocyte cultures) when challenged with
pro-inﬂammatory cytokines such as IL-18. The two aggre-
canases that act at the Glu373-Ala374 site, and that have
been isolated from articular cartilage culture systems mim-
icking the degradation occurring in OA, are, ADAMTS-4
and ADAMTS-59. The relative involvement of these
enzymes in the pathology of OA is highly controversial, par-
ticularly because ADAMTS-4-null mice did not exhibit pro-
tective effects on cartilage aggrecan loss compared with
wild-type mice in two separate osteoarthritic models10e12.
This contrasted with ADAMTS-5-null mice in which the
same models showed that lack of ADAMTS-5 protected
against cartilage breakdown11,12. However, previous publi-
cations have shown that ADAMTS-4 mRNA is more easily
elevated in chondrocytes treated with IL-1 than ADAMTS-5.
Contradictory evidence for the involvement of these two
enzymes is also found in the relative activity of recombinant
enzyme preparations on the native substrate aggrecan13,14.
After the initial attack on aggrecan by aggrecanases, further
degradation proceeds by MMP action. Two MMPs appear
to be particularly important in OA, the stromelysin MMP-3
and the collagenase, MMP-1315e17. MMP-3, in particular,
897Osteoarthritis and Cartilage Vol. 17, No. 7is readily induced by inﬂammatory cytokines in chondro-
cytes or connective tissue ﬁbroblasts18. MMP-13 is chieﬂy
involved in the late-stage catabolism of type II collagen.
Dietary polyunsaturated fatty acids (PUFAs) of both the
n-3 and the n-6 series are essential for human health. How-
ever, in general these two types of PUFA have opposite
effects on inﬂammatory responses. Thus, n-6 PUFAs give
rise to inﬂammatory eicosanoids while n-3 PUFAs are gen-
erally anti-inﬂammatory19,20 either because their eicosanoid
products have this property or because they compete with
n-6 PUFAs during metabolism21. Moreover, recently, new
classes of anti-inﬂammatory lipid mediators have been
shown to be formed from n-3 PUFAs such as eicosapentae-
noic (EPA) and docosahexaenoic (DHA) acids22.
Diets containing signiﬁcant levels of EPA and DHA have
been shown consistently to reduce joint stiffness and tender-
ness in arthritic patients (see23,24). Fish oils are important
sources of EPA and DHA and increased dietary levels are
recommended for patients with arthritis to alleviate pain and
inﬂammation in their joints19. Indeed, such n-3 PUFAs have
been shown to also reduce the production of inﬂammatory
cytokines such as IL-1 or TNF-a19. The latter cytokines
have been shown to stimulate the inducible cyclooxygenase
(COX), COX-225 which is thought responsible for the pain
experienced in arthritis26. The non-steroidal anti-inﬂamma-
tory drugs (NSAIDs), which are commonly used to relieve
pain in arthritis, unfortunately inhibit both COX-2 and the con-
stitutiveCOX-127 and, therefore, have side-effects28,29. How-
ever, new COX-2 selective inhibitors which were developed
to obviate the known side-effects of NSAIDs have been with-
drawn from the market due to safety concerns about the in-
creased risk of cardiovascular events30.
There have been considerable discussions about the rel-
ative efﬁcacy of different n-3 (omega-3) PUFAs for people
at risk of (or suffering from) different chronic inﬂammatoryTable
Oligonucleotide primers
Target template PCR primer sequences (50e30)
GAPDH 50-TGGCATCGTGGAAGGGCTCAT
50-ATGGGAGTTGCTGTTGAAGTC
IL-1a 50-AAGGAGAATGTGGTGATGGTG
50-CAGAAGAAGAGGAGGTTGGTC
IL-1b 50-GCTCTCCACCTCCTCTCACAG
50-TACATTCTTCCCTTCCCTTCT
TNF-a 50-CTCAAGCCTCAAGTAACAAGC
50-GCAATGATCCCAAAGTAGACC
COX-1 50-GCCCAACACTTCACCCATCAG
50-CCAGGAAGCAGCCCAAACACT
COX-2 50-GCTCTTCCTCCTGTGCCTGAT
50-CATGGTTCTTTCCCTTAGTGA
ADAMTS-4 50-TGGATCCTGAGGAGCCCTG
50-TGGCGGTCAGCATCATAGTC
ADAMTS-5 50-GGCCTCTCCCATGAYGATTCC
50-TGAGCGAGAACACTGGCCCCA
Aggrecan 50-CGCTATGACGCCATCTGCTAC
50-GCCTGCTTGGCCTCCTCAAA
Collagen type II 50-GAATTCGGTGTGGACATAGG
50-TACAGAGGTGTTTGACACAG
MMP-3 50-CTTTTGGCGAAAATCTCTCAG
50-AAAGAAACCCAAATGCTTCAA
MMP-13 50-TTCTGGCACACGCTTTTCCTC
50-GGTTGGGGTCTTCATCTCCTG
TIMP-1 50-CCACCTTATACCAGCGTTAT
50-CCTCACAGCCAACAGTGTAGG
TIMP-2 50-GTGGACTCTGGAAACGACAT
50-TCTTCTTCTGGGTGGTGCTCA
TIMP-3 50-GGGAAGAAGCTGGTAAAGGAGdiseases. Although a-linolenic acid (ALA) is often the
main dietary n-3 PUFA, it is rather poorly converted to
EPA, the direct precursor of eicosanoids31. Therefore,
most dietary advice speciﬁes EPA and/or DHA (see
e.g.,32), particularly for cardiovascular problems. In other
cases such as for the alleviation of Alzheimer’s disease,
DHA seems more effective than EPA33. In most intervention
trials for arthritis, both EPA and DHA have been used while
in epidemiological surveys all common types of n-3 PUFAs
were present in the diet. Therefore, the relative efﬁcacy of
different omega-3 PUFAs for arthritis is not known.
In the work reported here a model cell culture system was
used in which chondrocytes were pre-incubated with or
without different fatty acid preparations prior to exposure
to IL-1 (a cytokine known to induce catabolic changes in
chondrocytes). After exposure, the direct effects of different
n-3 PUFAs on relative message levels for inﬂammatory
markers and proteinases involved in the catabolism of
extracellular matrix molecules degraded during the onset
and progression of OA were tested. This system has also
allowed us to compare directly the relative efﬁciency of
the three main dietary n-3 PUFAs in beginning to under-
stand the mechanism by which n-3 PUFAs can alleviate
the underlying causes of chronic cartilage destruction in
arthritis. The data show clearly that all n-3 PUFAs are capa-
ble, at least at the mRNA level, of reducing the inﬂammatory
consequences caused by IL-1 challenge to the tissue, with
EPA being the most effective.
Materials and methodsMATERIALSClostridium histolyticum collagenase Type II, was from Worthington Bio-
chem. Corp. (NJ 08701, USA), pronase (Streptomyces griseus) from Boeh-
ringer (Poole, Dorset, UK) and Dulbecco’s modiﬁed Eagle’s medium
(DMEM) and fetal calf serum (FCS) from Gibco-BRL (now Invitrogen, PaisleyI
used for RT-PCR
Product size (bp) (bovine) Annealing temperature ((C)
370 50.0
470 53.2
454 54.5
454 57.6
287 59.0
229 52.3
151 55.5
498 59.2
197 57.0
429 53.0
404 50.0
273 53.0
282 54.0
265 54.0
418 54.0
898 Z. Zainal et al.: n-3 PUFA efﬁcacy in an arthritis modelPA4 9RF, UK). Fatty acids were from Nu-Chek Prep. (Elysian, MN 56028,
USA) and recombinant human interleukin-1a (IL-1a) from Totam Biological
(Peterborough, PE1 5TX, UK). Other chemicals (best available grades)
were from Sigma-Aldrich Co. (Poole, Dorset SP8 4XT, UK) or from Boehrin-
gereMannheim (now Roche Diagnostics Ltd., Burgess Hill RH15 9RY, UK).ISOLATION AND CULTURE OF BOVINE CHONDROCYTESBovine metacarpo e and metatarsophalengeal joints (7 day-old calves)
were obtained from the local abattoir. Cartilage was removed from the joint
surfaces under sterile conditions and digested in 0.1% (w/v) pronase in
DMEM containing 5% (v/v) FCS for 3 h at 37C with roller agitation. It was fur-
ther digested with 0.04% (w/v) collagenase in DMEM with 5% (v/v) FCS over-
night at 37C with roller agitation. After 24 h, cells were separated through
a 40 mm Nitex ﬁlter (Falcon, Oxford OX4 3LY, UK) before cell numbers were
estimated by microscopy. Monolayer cultures were established in 60 mm
dishes at 6 106 cells (ﬁnal density of approximately 20 105 cells/cm2) in
4 ml DMEM containing 50 mg/ml gentamicin. Cells were maintained at 37C
under 5% (v/v) CO2 for approximately 6 h to allow the chondrocytes to adhere
to the tissue culture plastic prior to the addition of experimental components.
Fatty acids to be added were made up in a complex with defatted bovine
serum albumin (BSA). 300 mg fatty/ml medium (20 mM HEPES, 140 mM
NaCl, 4.5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, 11 mM glucose, 3.5 mg
BSA, pH 7.4) was incubated overnight (16 h) at 37C under nitrogen. After
incubation, the mixture was ﬁltered through a Sartorious (0.2 mm pore size)
Minisart ﬁlter unit (Sartorius Ltd., Epsom KT19 9QQ, UK) to sterilise the
solution and ensure that any unbound, excess fatty acids were removed.
Gas liquid chromatography (GLC) analysis was made to quantify the fattyFig. 1. Uptake of a-linolenate into chondrocyte cultures. GLC traces are sh
of a-linolenate added. See Materials and methods for proceacid e BSA complex and was found necessary, as samples could
vary signiﬁcantly in their concentration of fatty acid after ﬁltration.
The fatty acid-BSA complex was added to the adhered chondrocytes to
give ﬁnal concentrations of 2.5e30 mg/ml fatty acids. A number of cultures
were left as controls (i.e., no addition of fatty acids). Cultures were main-
tained for 8 h (pre-incubation) in the absence or presence of fatty acids to
allow for uptake into cells and incorporation into membrane lipids. After 8 h
pre-incubation, the fatty acid media was removed and the cultures were
carefully washed three times with DMEM containing 50 mg/ml gentimicin. Fol-
lowing this, DMEM (containing 50 mg/ml gentimicin) was added either with or
without 10 ng/ml IL-1a and the cultures incubated for a further 96 h.METABOLISM OF EXPERIMENTAL CHONDROCYTE CULTURES
AS MEASURED BY LACTATE PRODUCTIONLactate production was used as a measure of the metabolic activity of
viable chondrocytes under the different experimental conditions. Lactate
concentrations in the culture media were quantiﬁed with a lactate assay kit
(SigmaeAldrich) used according to the manufacturer’s instructions.LIPID ANALYSISChondrocyte monolayers were extracted by a method34 which ensures
quantitative recovery even of very polar membrane lipids. The extracted
lipids were transmethylated using 2.5% (v/v) H2SO4 in dry methanol/toluene
(2:1, v/v) for 2 h at 70C. After extraction into petroleum ether, the fatty acid
methyl esters were separated with 10% SP-2330 on 100/120 Supelcoportown with control and IL-1a treated cultures and increasing amounts
dures. Incubations with added linolenate were for 8 h.
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autosystem XL gas chromatograph. Fatty acid methyl ester(s) (FAMEs) were
identiﬁed using standardmixtures (Nu-Chek) and quantiﬁcation performed us-
ing PerkineElmer internal software and a pentadecanoate internal standard.RNA ISOLATION, RT-PCR AND SEMI-QUANTIFICATION
OF MESSAGE LEVELS BY DENSITOMETRIC ANALYSIS
OF ETHIDIUM BROMIDE-STAINED GELSFor the ampliﬁcation of cDNA, total RNA was isolated from chondrocyte
cultures using Tri-reagent (1 ml/60 mm dish). 200 ml of CHCl3 was added,
inverted and left to stand for 15 min at room temperature, prior to centrifuga-
tion at 13,200 rpm for 15 min. The upper aqueous phase was removed and
mixed with an equal volume of 70% (v/v) ethanol and mRNA was isolatedFig. 2. Morphology of chondrocytes in culture. Pictures were taken by light
incubated with 10 mg/ml EPA followed by IL-1a treatment (C) and cells pre
points represent 0, 24, 48 and 72using the RNeasy miniprep kit and reagents (Qiagen Ltd., Crawley, UK)
according to the manufacturer’s protocol. Endogenous DNA was removed
using an on-column digest with DNase I (80 ml, Qiagen). Puriﬁed RNA was
eluted in RNase-free water. Reverse transcription-polymerase chain reac-
tions (RT-PCR) were performed using an RNA PCR core kit (Applied Biosys-
tems). Typically, a concentration of 500 ng of RNA was used for cDNA
ampliﬁcation. Primers used, along with annealing temperatures are listed
in Table I. The RT reaction mix was subjected to a cycle of 42C for
30 min, 99C for 5 min and soaked at 4C. PCR cycling parameters were
as follows: initial denaturation at 95C for 60 s, ampliﬁcation at 95C for
30 s, 45 s at the speciﬁed annealing temperature of the primers, 72C for
45 s (X40) and a ﬁnal extension step of 5 min at 72C.
Following PCR, the reaction products and a DNA ladder of standards were
size fractionated on 2% (w/v) agarose gels containing ethidium bromide.
Bandswere visualised under UV light, photographed and stored as image ﬁlesmicroscopy of control cells (A), cells treated with IL-1a (B), cells pre-
-incubated with 30 mg/ml EPA followed by IL-1a treatment (D). Time
h treatment, respectively.
900 Z. Zainal et al.: n-3 PUFA efﬁcacy in an arthritis modelfor further analysis. Individual gels (n¼ 3)were scanned usingKodakDigital IB
Image Analysis apparatus to provide densitometric values for each of the PCR
products of interest. These densitometric values were normalised to the den-
sitometric values obtained for GAPDH (glyceraldehyde 3-phosphate dehydro-
genase) (used as a constitutive gene) from the same cDNA samples.ResultsUPTAKE OF EXOGENOUS FATTY ACIDSIn experiments with various tissues where fatty acid sup-
plementation is required, the fatty acids are usually added
where complexed to serum albumin, since this is the way
in which they are carried within the body. Such in vitro ex-
periments have generally not reported tissue damage pro-
vided that the levels of fatty acids added are not
excessive. Although joint connective tissue is avascular, it
receives nutrients indirectly from the blood. Recently the
transport of fatty acids from albumin complexes has been
demonstrated and the mechanism studied. These experi-
ments showed clearly that fatty acids moved through the
cartilage matrix at measurable rates35. Therefore, fatty
acid-BSA mixtures were used in our experiments.
Preliminary experiments indicated that 8 h was sufﬁcient
time for uptake of fatty acids into chondrocytes to reach
equilibrium and would, therefore, be appropriate for further
experiments. Uptake into chondrocytes was examined
with different fatty acids (ALA, EPA, DHA and arachidonic
acid [AA]) and, at different concentrations, uptake was pro-
portional to the exogenous concentration added and there
was no detectable difference in the total uptake between
the four fatty acids36. A typical analysis (for ALA) is shown
in Fig. 1. The data showed that fatty acids were efﬁciently
taken up by the chondrocyte cultures in a dose-dependent
manner and it was, therefore, possible to test for the effectsFig. 3. Chondrocyte metabolism as measured by lactate production. La
was measured after the experimental period of 96 h. Cultures were ei
(as labelled in AeD). Meansof different concentrations of added fatty acids on the
expression levels of inﬂammatory mediators and protein-
ases up-regulated in chondrocytes by IL-1.CHONDROCYTE MORPHOLOGY AND METABOLIC ACTIVITYThe morphology of the chondrocytes was examined using
lightmicroscopy to determine if the cellsmaintained the typical
rounded chondrocytic morphology and did not become ﬁbro-
blastic-like during the experimental culture period. Following
the pre-incubation period (8 h) of chondrocytes in the pres-
ence or absence of fatty acid, a typical spherical morphology
wasobserved [Fig. 2(AeD),Plate1]. Following theexperimen-
tal cultureperiod, thismorphologicalappearance remained the
same for control cultures maintained in serum-free media
[Fig. 2(A), Plate 2e4]. However, chondrocytes challenged
with 10 ng/ml IL-1a [Fig. 2(B), Plate 2e4] changed shape con-
siderably over the experimental culture period of 96 h. IL-1
treatedcellswereheterogeneousandby72 h their cell shapes
becamemorespindle-like, sharp or stillate, possibly asa result
of the heterogeneity reported amongst articular chondro-
cytes37. In addition, cell debris and cell death could be seen
at 48 h [Fig. 2(B), Plate 3]with accumulation occurring through
the remaining culture period. In contrast, chondrocyte cultures
pre-treated with either 10 or 30 mg/ml EPA prior to the addition
of IL-1 [Fig. 2(C andD)] remained asmorphologically rounded
cells following 48 h of IL-1 treatment. At 72 h there was an ap-
pearance of ﬁbroblastic-like cells, cell debris and cell death.
However, these features were markedly reduced compared
to those seen in the IL-1 only cultures suggesting that the
pre-incubation of chondrocytes with the n-3 PUFA, EPA has
a protective effect from some of the adverse effects of the in-
ﬂammatory cytokine, IL-1a.ctate release into serum-free culture medium with or without IL-1
ther pre-treated with or without fatty acids or BSA solution alone
S.D. are shown (n¼ 3).
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tions (serum-free media containing no IL-1) for 96 h was
unaffected by an 8 h pre-incubation with fatty acids in a con-
centration range of 2.5e30 mg/ml. Figure 3, (open bars)
shows the lactate concentrations obtained for control cul-
tures and cultures pre-treated with 30 mg/ml fatty acid. How-
ever, during the experimental period (96 h) challenge with
IL-1a increased lactate production and this increased
amount was not altered by pre-incubation with any of the
fatty acids [Fig. 3(AeD), solid bars]. These results showADAMTS-4 (EPA)
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Fig. 4. Variable effects of different PUFAs on mRNA levels for the
proteinase ADAMTS-4. For procedures see Materials and
methods. (A) shows RT-PCRs for ADAMTS-4 whose expression
is induced by IL-1a and reduced by n-3 PUFAs. Pre-exposure to
fatty acids or BSA alone (controls) was for 8 h and incubation
with or without 10 ng/ml IL-1a was for 4 days. The histogram shows
data from scans of gels from three separate experiments with
meansS.D. given. Individual lanes show (L to R): controls (C),
controls þ30 mg/ml fatty acid (FA), þIL-1a, þIL-1a and 2.5 mg/ml
FA, þIL-a and 5 mg/ml FA, þIL-1a and 10 mg/ml FA, þ20 mg/ml
FA, þIL-1a and 30 mg/ml FA. * indicate signiﬁcantly different from
þIL-1a alone (P< 0.05) by Student’s t test.that general metabolism, at least as measured by lactate
production, was not affected by addition of any of the fatty
acids used.EFFECTS OF FATTY ACIDS ON EXPRESSION OF CARTILAGE
MATRIX PROTEINASESAs discussed earlier, the initial cleavage of aggrecan
during cartilage damage in arthritis is thought to be due
to the activity of ADAMTS-4 and/or ADAMTS-5. Arbitrary
densitometric values were obtained from gels using three
separate cultures of each experimental condition and
these values were normalised to densitometric values ob-
tained for the reference gene GAPDH by PCR of cDNA
from the same experimental cultures. For ADAMTS-4
this analysis is shown in Fig. 4 (Panel I, EPA, II, DHA,
III, ALA, IV, AA) where it can be seen in all control cultures
following 96 h in serum free medium there was negligible
mRNA levels and furthermore, the addition of fatty acids
for an 8 h period prior to the 96 h experimental time in
the form of EPA, DHA, ALA or AA did not alter the expres-
sion level of ADAMTS-4. However, after a 96 h exposure
of control cultures to IL-1 expression of ADAMTS-4 was
increased. In contrast, the IL-1 induced mRNA levels fol-
lowing pre-exposure to n-3 PUFAs were reduced in the
range 10e30 mg/ml EPA, 20e30 mg/ml DHA and 30 mg/ml
ALA. The n-6 PUFA AA had no detectable effect inADAMTS-5 (DHA)
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Fig. 5. Effects of exogenous PUFAs on mRNA levels for the pro-
teinase ADAMTS-5. For procedures see Materials and methods.
The results for three experiments (meansS.D.) are shown with
EPA, DHA or ALA being compared. See legend to Fig. 4 for details.
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Fig. 6. Effects of exogenous fatty acids on mRNA levels for the
MMP-3 and MMP-13. (A) shows results for MMP-3 and (B) data
for MMP-13. Exposure to EPA or DHA was for 8 h and incubations
with or without 10 ng/ml IL-1a were for 4 days. Abbreviations and
further details as for Fig. 4.
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Fig. 7. n-3 PUFAs reduce mRNA levels for the inducible COX-2 but
not for COX-1 in chondrocyte cultures. (A) shows results for COX-1
and (B) data for COX-2. Exposure to fatty acids was for 8 h and in-
cubations with or without 10 ng/ml IL-1a were for 4 days. Abbrevi-
ations and further details as for Fig. 4.
902 Z. Zainal et al.: n-3 PUFA efﬁcacy in an arthritis modelthe experiments [Fig. 4, Panel IV]. Indeed, this acid did
not alter IL-1 induced mRNA levels for any gene tested.
Therefore, these data are omitted from Figs. 5e8.
In separate experiments a similar study was carried out to
examine the effects of pre-culture of chondrocytes with n-3
PUFAs on the expression levels of ADAMTS-5 following
exposure to IL-1. ADAMTS-5, expression in control cultures
(having no exposure to fatty acids) was very variable. In
some cultures it was constitutively expressed [Fig. 5, Panel
II] whilst in others there appeared to be little or no expres-
sion [Fig. 5, Panel I & III]. However, the pre-treatment of
these chondrocyte cultures expressing high levels of
ADAMTS-5 [Fig. 5, Panel II] with n-3 PUFAs maintained
this level of expression of ADAMTS-5. In those control cul-
tures showing little expression of ADAMTS-5, the addition
of IL-1 caused a signiﬁcant increase in the expression
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Fig. 8. n-3 PUFAs reduce mRNA levels for inﬂammatory cytokines in chondrocyte cultures. RT-PCRs are shown for IL-1a (A), IL-1b (B) and
TNF-a (C). Exposure to fatty acids was for 8 h and incubations with 10 ng/ml IL-1a for 4 days. The histograms show meansS.D. (n¼ 3).
Abbreviations as for Fig. 4 and IL-a, IL-1a; IL-1b; TNF-a. Individual conditions are as for Fig. 4 with results for EPA, DHA and ALA shown.
903Osteoarthritis and Cartilage Vol. 17, No. 7levels of its mRNA [Fig. 5 Panel I & III] and this was reduced
by 10e30 mg/ml EPA, and by 30 mg/ml ALA. In contrast, the
addition of IL-1 to chondrocyte cultures showing high
expression of ADAMTS-5 in the control cultures caused
no signiﬁcant increase or decrease in expression aftera 96 h exposure with IL-1 either in the presence or absence
of an 8 h pre-incubation with fatty acid. Because of the high
constitutive levels in the controls and little increase with the
addition of IL-1, no deﬁnitive conclusions can be made on
the effects of DHA in this culture system.
904 Z. Zainal et al.: n-3 PUFA efﬁcacy in an arthritis modelMMPs carry out further catabolism of cartilage compo-
nents after the initial attack by aggrecanases. Two isoforms,
MMP-3 and MMP-13, are thought to be particularly active in
OA. Expression levels for their mRNAs were examined by
RT-PCR and data are shown in Fig. 6 for EPA and DHA.
MMP-3 was signiﬁcantly expressed in control tissues but
the levels of its mRNA were increased during inﬂammatory
stimulation by IL-1a. EPA at 20 and 30 mg/ml reduced
mRNA levels but no other fatty acid (including ALA, AA:
data not shown) appeared to affect these [Fig. 6(A)]. For
MMP-13, expression was again signiﬁcant in control tissues
but exposure to IL-1a had little effect in this case. While
EPA at 20 or 30 mg/ml was able to reduce mRNA levels
for MMP-13 [Fig. 6(B)], exposure to other PUFAs (DHA,
ALA, AA) had no signiﬁcant effect.EFFECTS OF PUFAs ON COX mRNA LEVELSCOXs are important for the conversion of the n-3 or n-6
PUFAs to eicosanoids. While COX-1 has a constitutive
(house-keeping) role, COX-2 is thought to be responsible
for increased eicosanoid production during inﬂammation38.
In accordance with the above, mRNA levels for COX-1
were signiﬁcant in control tissues and were unaffected by
inﬂammatory stimulation [Fig. 7(A)]. No change in COX-1
mRNA levels was found on treatment of the chondrocyte
cultures with any PUFA. In contrast, there was little expres-
sion of COX-2 mRNA in control tissues and this was
strongly induced by exposure to the inﬂammatory cytokine,
IL-1a [Fig. 7(B)]. Levels of COX-2 mRNA were abrogated
effectively by 10e30 mg/ml EPA, by 30 mg/ml DHA and
partly by 30 mg/ml ALA. AA had no effect. These data
showed that, in bovine chondrocyte cultures, only COX-2
was affected by inﬂammatory stimulation and only this
COX was reduced by exposure to n-3 PUFAs.MODULATION OF INFLAMMATORY CYTOKINES BY n-3 PUFAsA number of cytokines are thought to be involved in the
pathology of OA. Of these, IL-1 and TNF-a are pre-
eminent39. Accordingly, RT-PCR was used to examine
expression levels for IL-1a, IL-1b and TNF-a. Induction of
inﬂammation, with exogenous IL-1a, caused signiﬁcant
expression of IL-1a mRNA [Fig. 8(A)]. This was reduced
to negligible amounts by 10e30 mg/ml EPA or DHA and
by 30 mg/ml ALA. Arachidonate treatment did not affect
the mRNA levels induced by inﬂammation (data not shown).
Like IL-1a, there was little if any IL-1b mRNA in control
chondrocyte cultures [Fig. 8(B)]. This was strongly induced
by exposure of cells to exogenous IL-1a. The induced
mRNA levels were reduced to negligible levels by pre-
exposure of cells to 20 and 30 mg/ml EPA, partly by
30 mg/ml DHA and were unchanged by exposure to
2.5e30 mg/ml ALA or AA (data not shown).
mRNA for TNF-awasalso absent from control cultures and
was induced by inﬂammatory stimulation of the chondrocyte
cultures [Fig. 8(C)]. This mRNAwas reduced strongly by pre-
exposure to 10e30 mg/ml EPA, and by 20e30 mg DHA or
ALA. Exposure to the n-6 PUFA, arachidonate, did not affect
mRNA levels for TNF-a (data not shown).Discussion
In this study, we have shown that chondrocytes are
able to take up exogenous PUFAs speedily, ina dose-dependent manner. We added the fatty acids in
a complex to BSA and at concentrations appropriate to
physiological levels35. Moreover, additionally, after chal-
lenge of chondrocyte monolayer cultures with the cytokine
IL-1, fatty acid pre-treated chondrocytes appeared to have
altered expression of mRNAs for proteins involved in the
pathology of OA.
Of particular note was the ability of different n-3 PUFAs to
reduce mRNA expression for cartilage-degrading protein-
ases (aggrecanases, MMP) and inﬂammatory cytokines.
Moreover, n-3 PUFAs reduce expression of the ‘inﬂamma-
tory’ COX-2 but not the constitutive COX-1 [Fig. 7] and,
therefore, in theory produce a much better outcome than,
say, the use of NSAIDS where both are reduced28. This
result gives an initial reason why dietary n-3 PUFAs are
efﬁcacious for arthritis sufferers. That is, not only do n-3
PUFAs compete with the inﬂammatory n-6 PUFAs for
enzymes that produce eicosanoids (and also themselves
produce less inﬂammatory eicosanoids)21,40,41 but they
also reduce COX-2 mRNA levels. This is also consistent
with the effects of n-3 PUFAs in other tissues where they
are selective for COX-2 but not COX-142,43.
There has been considerable discussion about the rela-
tive effectiveness of different n-3 PUFAs for good health
(cf. 31). It is, for example, well known that dietary ALA is
less effective than EPA and DHA (on a g/g basis) both
because of the former’s rapid b-oxidation and also its
rather poor conversion to EPA and, especially, DHA31.
Here we have tested the relative efﬁcacy directly and it is
very clear that, in our experimental system, EPA was
more effective than DHA which in turn was better than
ALA. This was true for all of the message levels that we
examined.
The relatively poor efﬁciency of ALA compared to EPA
can be explained if the mechanism by which mRNA expres-
sion is regulated is via eicosanoid production since EPA
can produce eicosanoids directly40. If that is the case then
DHA is likely to have its effects via the newly discovered
mediators such as resolvins D22 because DHA is not
metabolised directly to eicosanoids41 but only after retro-
conversion to EPA.
However, the n-3 PUFAs are also likely to have more
direct effects on gene expression and differences between
individual PUFAs on such expression have been exten-
sively documented44,45. This has included, for example, a di-
rect effect of DHA on IL-1a-induced expression of COX-2
(but not COX-1) in endothelial cells43. Work in our labora-
tory has suggested that signalling pathways using MAP ki-
nases such as ERK may be involved46 and this agrees with
recent data in other inﬂammatory tissues43.
Thus, it seems most likely that n-3 PUFAs can have
a beneﬁcial effect on the inﬂammation and cartilage degra-
dation associated with OA in several ways. Moreover, our
results in showing the relative efﬁcacy of EPA in such
situations provides a molecular mechanism to justify
conclusions drawn from dietary studies (see24). This should
also provide impetus to efforts being made to ensure
supplies of EPA for the nutrition industry47,48 at a time
when some traditional ﬁsh stock sources are under threat.Conﬂict of interest
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